Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

UK cost agency rejects leukemia drug from J&J and AbbVie

A new leukemia drug viewed by industry experts as a future blockbuster has been rejected by Britain’s healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources. Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed […]

Read More »

AstraZeneca sells drug for $70 million as divestment drive continues

AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart medicines.   The British-based drugmaker has been divesting peripheral products to help pay the bills as it invests in new medicines, while taking […]

Read More »

For Clinical Trials, Centralized Imaging Data Collection and Review Is a Must

  By Joseph Pierro, chief medical officer of Biomedical Systems.   In many clinical trials, clinical imaging plays an important role in the drug development process. Whether the trial involves drugs, biologics, or devices, imaging may be used to measure the efficacy and safety of the investigational product. An independent assessment based on the centralized […]

Read More »

China to consolidate drug market, promote traditional medicines

China plans to consolidate its huge and fragmented drug market and will support a greater role for traditional Chinese medicines (TCM), the central government said in a statement on Sunday following a meeting of the State Council.   China will also strengthen safety controls and traceability of domestic drugs, the statement said, part of an […]

Read More »

2016 Annual Report: Top 10 Pipelines

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

Read More »

UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen’s

Britain’s cost watchdog has recommended that patients with high cholesterol should not get Sanofi and Regeneron’s new cholesterol-lowering injection Praluent, although Amgen’s similar drug Repatha will be available. The National Institute for Health and Care Excellence (NICE) cost watchdog said in draft guidance on Monday that Praluent’s benefits were uncertain and it was likely to […]

Read More »

Three Potential Blockbusters that Could Singlehandedly Catapult Big Pharma in 2016

Over the past few years, annual revenue growth of pharma giants Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), and Bristol-Myers Squibb (NYSE:BMY) has been mostly flat to somewhat negative. Although each of these companies market dozens of products, making it hard for any one to move the needle on its own, the emergence of a multi-billion […]

Read More »

Roche expects cancer treatments to be spared U.S. pricing curbs

The U.S. Congress may intervene on how much companies can charge for some drugs following a move last year by Turing Pharmaceuticals to ratchet up the price of a treatment for deadly parasite infections by 5,000 percent, Roche’s head of pharmaceuticals said.   Roche’s Dan O’Day is convinced the oncology portfolio at the world’s biggest […]

Read More »

Obama calls for rapid Zika research as virus seen spreading

President Barack Obama on Tuesday called for the rapid development of tests, vaccines and treatments to fight the mosquito-transmitted Zika virus, which has been linked to birth defects and could spread to the United States in warmer months. U.S. health officials are stepping up efforts to study the link between Zika virus infections and birth […]

Read More »

Major drugmakers push back in U.S. price debate

With a backlash brewing over the price of medicines in the United States, drugmakers are pushing back with a new message: Most people don’t pay retail.    Top executives from Eli Lilly and Co (LLY.N), Merck & Co (MRK.N) and Biogen Inc (BIIB.O) said in interviews with Reuters this week that the media focus on retail, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom